Lifemin

Lisdexamfetamine dimesylate, the active ingredient in Lifemin, is a central nervous system stimulant presented as an oral dosage form for oral use. It treats attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults.

GNH USA supplies Lifemin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lifemin (lisdexamfetamine dimesylate) is indicated for disorders within the attention‑deficit/hyperactivity disorder (ADHD) therapeutic area.

- Attention deficit hyperactivity disorder (children): Improves focus and reduces hyperactive behaviour in school‑aged patients. - Attention deficit hyperactivity disorder (adolescents): Decreases impulsivity and supports academic performance during teenage years. - Attention deficit hyperactivity disorder (adults): Enhances concentration and functional productivity in adult patients.

Lifemin may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Decreased appetite: Reduced hunger leading to weight loss. - Insomnia: Difficulty falling or staying asleep. - Dry mouth: Sensation of oral dryness. - Headache: Mild to moderate cranial pain. - Irritability: Mood changes and increased frustration. - Nausea: Stomach upset or feeling sick.

Serious or Rare Side Effects: - Cardiovascular events: Elevated blood pressure or heart rate abnormalities. - Psychiatric symptoms: New or worsening anxiety, depression, or psychosis. - Growth suppression: Potential impact on height development in children. - Seizures: Increased risk in susceptible individuals. - Allergic reactions: Rash, swelling, or anaphylaxis. - Peripheral vasculitis: Inflammation of small blood vessels.

Before prescribing Lifemin, clinicians should evaluate patient history and monitor for specific safety concerns.

- Cardiovascular assessment: Check blood pressure and heart rate baseline and periodically. - Psychiatric evaluation: Screen for history of mood disorders, psychosis or substance misuse. - Growth monitoring: Measure height and weight regularly in pediatric patients. - Drug abuse potential: Consider risk of misuse due to stimulant properties. - Pregnancy counseling: Discuss potential risks; category C indicates animal data show risk but benefits may outweigh. - Store at ambient temperature: Keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Lifemin can interact with several medication classes, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): Risk of hypertensive crisis; avoid concurrent use. - Tricyclic antidepressants: May increase cardiovascular side effects. - Proton pump inhibitors (e.g., omeprazole): Can raise plasma levels of dextroamphetamine.

Moderate Interactions (Monitor Closely): - Antihypertensives: May reduce blood‑pressure‑lowering effect. - Antipsychotics: Potential for reduced stimulant efficacy. - CYP2D6 inhibitors (e.g., fluoxetine): May modestly increase active metabolite exposure.